Drugs

, Volume 51, Issue 4, pp 552–570 | Cite as

Causes and Problems of Nonresponse or Poor Response to Drugs

  • Pau Salvà Lacombe
  • Juan Antonio García Vicente
  • Joan Costa Pagès
  • Paolo Lucio Morselli
Review Article

Summary

The lack of (or poor) response to drugs has very important medical, social and economic consequences today. An unsatisfactory response to treatment implies not only a worsening or prolongation of the pathological state, but also prolonged hospitalisation, longer withdrawal from social and active life, and waste of community resources.

Poor response to drugs has many and varied causes, among which 4 major categories can be identified: pharmacokinetic, cellular, genetic and medical.

After a brief description of the terminology, the phenomena of tachyphylaxis, tolerance and drug resistance are analysed and critically described on the basis of the available evidence. Whenever possible, alternative or operative behaviours aimed at reducing the incidence of the above phenomena are commented on. On the question of medical causes, irrational prescriptions and poor compliance with the prescribed regimen stand as two major issues whose prevalence is worrying. In order to limit the waste of professional responsibility and economic resources, efforts aimed at reducing the present insufficiencies are needed at organisational and educational levels.

Keywords

Drug Resistance Poor Response Guanylate Cyclase Poor Compliance Biochemical Alteration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abrams J. The mystery of nitrate resistance. Am J Cardiol 1991; 68: 1393–6CrossRefPubMedGoogle Scholar
  2. 2.
    Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance and strategies for prevention. Ann Int Med 1991; 114: 667–77PubMedGoogle Scholar
  3. 3.
    Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991Google Scholar
  4. 4.
    Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991; 148: 695–704PubMedGoogle Scholar
  5. 5.
    Kruse W. Patient compliance with drug treatment: new perspectives on an old problem. Clin Invest 1992; 70: 163–6CrossRefGoogle Scholar
  6. 6.
    Task Force for Compliance. Non compliance with medications: an economic tragedy with important implications for health care reform. Baltimore (MD): Task Force for Compliance, 1993 NovGoogle Scholar
  7. 7.
    International Medical Benefit/Risk Foundation. Improving patient information and education on medicines. Geneva: IMBRF, 1993 OctGoogle Scholar
  8. 8.
    Hall TC. Prediction of response to therapy and mechanisms of resistance. Semin Oncol 1977; 4: 193–202PubMedGoogle Scholar
  9. 9.
    Pratt WB. Drug resistance. In: Pratt WB, Taylor P, editors. Principles of drug action: the basis of pharmacology. 3rd ed. London: Churchill-Livingstone, 1990: 565–638Google Scholar
  10. 10.
    Borst P. Genetic mechanisms of drug resistance: a review. Acta Oncol 1991; 30: 87–105CrossRefPubMedGoogle Scholar
  11. 11.
    Vendrik CPJ, Bergers JJ, De Jong WH, et al. Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 1992; 29: 413–29CrossRefPubMedGoogle Scholar
  12. 12.
    Overstreet DH, Yamamura NI. Receptor alterations and drug tolerance. Life Sci 1979; 25: 1865–78CrossRefPubMedGoogle Scholar
  13. 13.
    Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane receptor regulation: biochemical, physiological and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 1984; 310: 1570–9CrossRefPubMedGoogle Scholar
  14. 14.
    Cros G. Mécanismes de la désensibilization des recepteurs béta-adrenergiques. Bull Eur Physiopathol Respir 1985; 21: 35–43Google Scholar
  15. 15.
    Katz RJ. Mechanisms of nitrate tolerance: a review. Cardiovasc Drugs Ther 1990; 4: 247–52CrossRefPubMedGoogle Scholar
  16. 16.
    Bourne HR, Roberts JM. Drug receptors and pharmacodynamics. In: Katzung BG, editor. Basic and clinical pharmacology. 5th ed. New Jersey: Prentice-Hall International, 1992: 10–34Google Scholar
  17. 17.
    Netter KJ. Mechanisms of mono-oxygenases induction and inhibition. Pharmacol Ther 1987; 33: 1–9CrossRefPubMedGoogle Scholar
  18. 18.
    Perucca E, Richens A. Biotransformations. In: Levy R, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1989: 31–50Google Scholar
  19. 19.
    Bock KW, Lilienblum W, Fischer G, et al. Induction and inhibition of conjugating enzymes with emphasis on UDP-glucuronyltransferases. Pharmacol Ther 1987; 33: 23–7CrossRefPubMedGoogle Scholar
  20. 20.
    Okey AB. Enzyme induction in the cytochrome P450 system. Pharmacol Ther 1989; 45: 241–98CrossRefGoogle Scholar
  21. 21.
    Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33: 139–44CrossRefPubMedGoogle Scholar
  22. 22.
    Hittle JB, Crabb DW. The molecular biology of alcohol dehydrogenase: implications for the control of alcohol metabolism. J Lab Clin Med 1988; 122: 7–15Google Scholar
  23. 23.
    Morselli PL, Rizzo M, Garattini S. Interactions between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann NY Acad Sci 1971; 179: 88–107CrossRefPubMedGoogle Scholar
  24. 24.
    McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs 1988; 36: 83–110CrossRefPubMedGoogle Scholar
  25. 25.
    Morselli PL. Role of drug metabolism in drug disposition and effects. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism. EUR 15439-EN. Bruxelles, Luxembourg: European Commission, 1995: 3–33Google Scholar
  26. 26.
    Rizack MA, Hilman CDM. Handbook of adverse drug interactions. New York: Med Lett, 1987Google Scholar
  27. 27.
    Patat A. Interactions médicamenteuses: problèmes méthodologiques. Therapie 1995; 50: 203–14PubMedGoogle Scholar
  28. 28.
    Pauwels R. Récepteurs adrenergiques bronchiques et asthme: la tachyphylaxie et sa prevention. Allerg Immunol (Paris) 1988; 20: 261–5Google Scholar
  29. 29.
    Lefkowitz RJ, Stadel JM, Caron MG. Adenylate cyclase coupled beta-adrenergic receptors: structure and mechanisms of activation and desensitization. Annu Rev Biochem 1983; 52: 159–86CrossRefPubMedGoogle Scholar
  30. 30.
    Pazos A. Acciones de los farmacos: interacciones fármacos y receptor. In: Florez J, Armijo JA, Mediavilla A, editors. Farmacologia humana. 2nd ed. Barcelona: Salvat, 1992: 7–17Google Scholar
  31. 31.
    Bassenge E, Grewe R. Bases pharmacologiques de l’échappement thérapeutique. Presse Med 1988; 17: 985–91PubMedGoogle Scholar
  32. 32.
    Brunizeel PLB, Meurs H, Leferink JG, et al. Some fundamental points concerning the clinical aspects of desensitization. Bull Eur Physiopathol Respir 1985; 21: 45s–52sGoogle Scholar
  33. 33.
    Garreau M, De Wilde J, Frattola L, et al. Anxiolytics and dependence: two double-blind studies of alpidem versus benzodiazepines. In: Racagni G, Brunello N, Fukuda T, editors. Biological psychiatry. Vol. 1. Amsterdam: Excerpta Medica, 1991: 696–8Google Scholar
  34. 34.
    Lorenzo P, Leza JC, Lisazoan I. Drogodependencias. In: Velasco A, Lorenzo P, Serrano JS, et al., editors. Velázquez farmacologia. 16th ed. Madrid: Interamericana-McGraw-Hill, 1993: 499–529Google Scholar
  35. 35.
    Morselli PL. Anxiolytic therapy in the elderly. In: Bartholini G, Garreau M, Zivkovic B, editors. Imidazopyridines in anxiety disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1993: 215–22Google Scholar
  36. 36.
    Frattola L, Garreau M, Piolti R, et al. Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients. Br J Psychiatry 1994; 164: 94–100CrossRefGoogle Scholar
  37. 37.
    Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. J Allergy Clin Immunol 1983; 27: 417–22Google Scholar
  38. 38.
    Aarli JA. Effect of clonazepam (Ro-4023) on epileptic seizures. Acta Neurol Scand 1973; 49: 11–7CrossRefGoogle Scholar
  39. 39.
    Sato S. Benzodiazepine: clonazepam. In: Levy R, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1989: 725–34Google Scholar
  40. 40.
    Nierenberg AA, Amsterdam JD. Treatment resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51 Suppl. 6: 39–47PubMedGoogle Scholar
  41. 41.
    Monti JM, Attali P, Monti DB, et al. Zolpidem and rebound insomnia: a double blind, controlled Polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994; 27: 166–75CrossRefPubMedGoogle Scholar
  42. 42.
    Venter JC. High efficacy coupling between beta-adrenergic receptors and cardiac contractility: direct evidence for beta-adrenergic ‘spare’ receptors. Mol Pharmacol 1979; 16: 429–40PubMedGoogle Scholar
  43. 43.
    Parker JO, Farrel LB, Lahey KA, et al. Effect of interval between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987; 316: 1440–4CrossRefPubMedGoogle Scholar
  44. 44.
    Thadani U, Whitsett J, Hamilton ST. Nitrate therapy for myocardial ischemic syndrome: current perspective including tolerance. Curr Probi Cardiol 1988; 13: 723–84Google Scholar
  45. 45.
    Flaherty JT. Nitrate tolerance: a review of the evidence. Drugs 1989; 37: 523–50CrossRefPubMedGoogle Scholar
  46. 46.
    Stewart DD. Remarkable tolerance to nitroglycerin. Philadelphia: Polyclinic, 1988: 172Google Scholar
  47. 47.
    Laws GC. The effect of nitroglycerin upon those who manufacture it. JAMA 1989; 31: 793Google Scholar
  48. 48.
    Danahy DT, Aronow WS. Haemodynamic and antianginal effect of high dose oral isosorbide dinitrate after chronic use. Circulation 1977; 56: 205–12CrossRefPubMedGoogle Scholar
  49. 49.
    Thadani U, Fung HL, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose response during acute and sustained therapy. Am J Cardiol 1982; 49: 411–9CrossRefPubMedGoogle Scholar
  50. 50.
    Frishman WH, Giles T, Greenberg S, et al. Sustained high dose nitroglycerin transcutaneous patch therapy in angina pectoris: evidences for attenuation of the effect over time. J Clin Pharmacol 1989; 29: 1097–105PubMedGoogle Scholar
  51. 51.
    James MA, Papouchado M, Jones JV. Attenuation of nitrate effect during an intermittent treatment regimen and the time course of nitrate tolerance. Eur Heart J 1991; 12: 1266–72CrossRefPubMedGoogle Scholar
  52. 52.
    Colucci WS, Williams GH, Alexander RW, et al. Mechanism and implication of vasodilator tolerance in the treatment of congestive heart failure. Am J Med 1991; 71: 89–99CrossRefGoogle Scholar
  53. 53.
    Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to haemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987; 75: 577–84CrossRefGoogle Scholar
  54. 54.
    Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799–809CrossRefPubMedGoogle Scholar
  55. 55.
    Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984; 54: 471–6CrossRefPubMedGoogle Scholar
  56. 56.
    Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrates, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediate. J Pharmacol Exp Ther 1981; 218: 739–49PubMedGoogle Scholar
  57. 57.
    Murad F, Waldman SA, Fiscus RR, et al. Regulation of cyclic GMP synthesis and the interaction with calcium. J Cardiovasc Pharmacol 1988; 8 Suppl. 8: S57–60Google Scholar
  58. 58.
    Moncada S, Radomsky MV, Palmer RM. Endothelium-derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988; 37: 2495–501CrossRefPubMedGoogle Scholar
  59. 59.
    Needleman P, Jakshik B, Johnson EM. Sulphydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973; 187: 324–31PubMedGoogle Scholar
  60. 60.
    Fung H. Pharmacokinetics and pharmacodynamics of organic nitrates. Am J Cardiol 1987; 60: 4H–9HCrossRefPubMedGoogle Scholar
  61. 61.
    Torresi J, Horowitz JD, Dusting GI. Prevention and reversal of tolerance to nitroglycerin with N-acetylcysteine. J Cardiovasc Pharmacol 1985; 7: 777–83CrossRefPubMedGoogle Scholar
  62. 62.
    Munzel T, Holtz J, Mulsch A, et al. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation 1989; 79: 188–97CrossRefPubMedGoogle Scholar
  63. 63.
    Dupuis J, Lalonde G, Lemiux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990; 16: 932–4CrossRefGoogle Scholar
  64. 64.
    Luke R, Sharpe N, Coxon R. Transdermal nitroglycerin in angina pectoris: efficacy of intermittent application. J Am Coll Cardiol 1987; 10: 642–6CrossRefPubMedGoogle Scholar
  65. 65.
    Sharpe N, Coxon R, Webster M, et al. Haemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 1987; 59: 895–9CrossRefPubMedGoogle Scholar
  66. 66.
    Amsterdam EA. Rationale for intermittent nitrate therapy. Am J Cardiol 1992; 70: 44–59CrossRefGoogle Scholar
  67. 67.
    Pallarés R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474–80CrossRefPubMedGoogle Scholar
  68. 68.
    Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481–6CrossRefPubMedGoogle Scholar
  69. 69.
    Hogerzeil HV. Promoting rational prescribing: an international perspective. Br J Clin Pharmacol 1995; 36: 1–6CrossRefGoogle Scholar
  70. 70.
    Woodhouse JR, Ferry DR. The genetic basis of resistance to cancer chemotherapy. Ann Med 1995; 27: 157–67CrossRefPubMedGoogle Scholar
  71. 71.
    Veterans Administration Cooperative Study Group on Anti-Hypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. JAMA 1982; 248: 1966–2003Google Scholar
  72. 72.
    Venter CP, Joubert PH. Ethnic differences in β1 adrenoceptor blockade by propranolol. J Cardiovasc Pharmacol 1984; 6: 361–4CrossRefPubMedGoogle Scholar
  73. 73.
    Rutledge DR, Steinberg JS, Cardozo L. Racial differences in drug response: isoproterenol effects on heart rate following intravenous metoprolol. Clin Pharmacol Ther 1989; 45: 380–6CrossRefPubMedGoogle Scholar
  74. 74.
    Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther 1992; 51: 495–500CrossRefPubMedGoogle Scholar
  75. 75.
    Edeki TI, Brase DA. Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Drug Metab Rev 1995; 27: 449–69CrossRefPubMedGoogle Scholar
  76. 76.
    Gram LF, Brosen K. Conditions under which genetic polymorphisms are clinically relevant. In: Alvan G, Balant LP, Bechtel PR, et al., editors. European Consensus Conference on Pharmacogenetics. ECSC-EEC-EAEC-EUR 12379. Bruxelles, Luxembourg: 1990; 87–96Google Scholar
  77. 77.
    Bertilsson L, Dahl ML, Ingelman-Sundberg M, et al. Interindividual and interethnic differences in polymorphic drug oxidation: implications for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism. EUR 15439-EN. Bruxelles, Luxembourg: European Commission, 1995; 85–136Google Scholar
  78. 78.
    Kalow W, Grant DM. Genetic variations of drug metabolizing enzymes. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism. EUR 15439-EN. Bruxelles, Luxembourg: European Commission, 1995; 57–84Google Scholar
  79. 79.
    Alós JI. Resistencia bacteriana a los antibióticos: the never ending story. Med Clin (Barc) 1994; 103: 94–6Google Scholar
  80. 80.
    López-Yeste ML, Chaves J, Garau JM, et al. Pérdida de sensibilidad a los antibioticos de cepas de Pseudomonas aeruginosa en el curso del tratamiento. Med Clin (Barc) 1994; 103: 81–4Google Scholar
  81. 81.
    Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375–82CrossRefPubMedGoogle Scholar
  82. 82.
    Schimke RT, Kaufman RJ, Alt FW, et al. Gene amplification and drug resistance in cultured murine cells. Science 1978; 202: 1051–5CrossRefPubMedGoogle Scholar
  83. 83.
    Carman MD, Schornagel JH, Rivest RS, et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 1984; 2: 16–20PubMedGoogle Scholar
  84. 84.
    Horns RC, Dower WJ, Schimke RT. Gene amplification in a leukaemic patient treated with methotrexate. J Clin Oncol 1984; 2: 2–7PubMedGoogle Scholar
  85. 85.
    Barg N. Antibiotic therapy in 1994: mechanisms of resistance. Hosp Formul 1994; 29: S13–7PubMedGoogle Scholar
  86. 86.
    Hanschumacher RE, Calabresi P, Webb AD, et al. Summary of current information on 6-azauridine. Cancer Chemother Res 1962; 21: 1–18Google Scholar
  87. 87.
    Field RB, Gang M, Kline I, et al. The effect of phenobarbital or 2-diethylaminoethyl 2-1-2-diphenyl valerate on the activation of cyclophosphamide in vivo. J Pharmacol Exp Ther 1972; 180: 475–83PubMedGoogle Scholar
  88. 88.
    Jacobs RF. Multiple drug-resistant tuberculosis. Clin Infect Dis 1994; 19: 1–10CrossRefPubMedGoogle Scholar
  89. 89.
    Kessel D, Hall TC. Transport and phosphorylation as factors in the antitumour action of cytosine arabinoside. Science 1967; 56: 1240–1CrossRefGoogle Scholar
  90. 90.
    Cornwell MM, Gottesman MM, Pastan I. Increase vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 1986; 261: 7921–8PubMedGoogle Scholar
  91. 91.
    Cornwell JA, Safa AR, Felsted WI, et al. Membrane vesicles from multi-drug-resistant human cancer cells contain a specific 150-170 KDa protein detected by photo affinity. Proc Natl Acad Sci USA 1986; 83: 3847–50CrossRefPubMedGoogle Scholar
  92. 92.
    Kaye SB. The multidrug resistance phenotype. Br J Cancer 1988; 58: 691–4CrossRefPubMedGoogle Scholar
  93. 93.
    Coleman K, Athalye M, Clancey A, et al. Bacterial resistance mechanisms as therapeutic targets. J Antimicrob Chemother 1994; 33: 1091–116CrossRefPubMedGoogle Scholar
  94. 94.
    Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994; 264: 382–8CrossRefPubMedGoogle Scholar
  95. 95.
    Poole K. Bacterial multidrug resistance: emphasis on efflux mechanisms and Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 34: 453–6CrossRefPubMedGoogle Scholar
  96. 96.
    Bell DR, Gerlach JH, Karther N, et al. Detection of P-glycoprotein in ovarian cancer: molecular marker associated with multidrug resistance. J Clin Oncol 1985; 3: 311–5PubMedGoogle Scholar
  97. 97.
    Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of a P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415–24PubMedGoogle Scholar
  98. 98.
    Goldstein LJ, Galsk JH, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 11–124CrossRefGoogle Scholar
  99. 99.
    Kuwazuru Y, Yoshimura A, Hanada S, et al. Expression of the multiple drug transporter, P-glycoprotein, in adult leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868–73CrossRefPubMedGoogle Scholar
  100. 100.
    Gerlach JH, Bell DR, Karakousis C, et al. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987; 5: 1452–60PubMedGoogle Scholar
  101. 101.
    Chan HSL, Bradley G, Thorner P, et al. A sensitive method for immunochemical detection of P-glycoprotein in multidrug resistant human ovarian carcinoma cell lines. Lab Invest 1988; 59: 870–5PubMedGoogle Scholar
  102. 102.
    Garman D, Center MS. Alterations in cell surface membranes in Chinese hamster lung cells resistant to adriamycin. Biochem Biophys Res Commun 1982; 105: 157–63CrossRefPubMedGoogle Scholar
  103. 103.
    Richert N, Akiyama S, Shen DW, et al. Multiple drug-resistant human KB carcinoma cells have decreased amount of a 75 kDa and a 72 kDa glycoprotein. Proc Nat Acad Sci USA 1985; 82: 2230–3CrossRefGoogle Scholar
  104. 104.
    Hromas RA, Andrews PA, Murphy MP, et al. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 1987; 34: 9–13CrossRefPubMedGoogle Scholar
  105. 105.
    Hamilton TC, Lai GM, Rothenberg ML, et al. Mechanisms of resistance to alkylating agents and cis-platinum. In: Ozols RF, editor. Cancer treatment and research: drug resistance. Boston: Martinus Nijhoff, 1989: 151–69CrossRefGoogle Scholar
  106. 106.
    Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P-388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967–72PubMedGoogle Scholar
  107. 107.
    Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites, and transport of verapamil outward across the plasma membrane of K-526/ADM cells. Cancer Res 1989; 49: 5002–6PubMedGoogle Scholar
  108. 108.
    Safa AR, Glover CJ, Sewell JL, et al. Identification of the multidrug-resistance related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987; 262: 7884–8PubMedGoogle Scholar
  109. 109.
    Rogan AM, Hamilton TC, Young IC, et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984; 224: 994–6CrossRefPubMedGoogle Scholar
  110. 110.
    Thomson KS, Sanders WE, Sanders CC. USA resistance patterns among UTI pathogens. J Antimicrob Chemother 1994; 33: S9–15Google Scholar
  111. 111.
    Livermore DM. Evolution of beta-lactamase inhibitors. Intensive Care Med 1994; 20: 10–3CrossRefGoogle Scholar
  112. 112.
    Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res 1995; 29; 43–50CrossRefPubMedGoogle Scholar
  113. 113.
    Schatzberg AF, Cole JO, Cohen BM, et al. Survey of depressed patients who have failed to respond to treatment. In: Davis JM, Mans J, editors. The affective disorders. Washington DC: Academic Psychiatric Press, 1983: 73–85Google Scholar
  114. 114.
    Keller MB, Zucker ME. Cross-over studies of chronic resistant depression. Proceedings of the VIII ECNP Congress; 1995 Sept 30-Oct 4: Venice. European Neuropharmacology 1995; 5: 198–9CrossRefGoogle Scholar
  115. 115.
    Quitkin FM. The importance of dosage in prescribing antidepressants. Br J Psychiatry 1985; 147: 593–7CrossRefPubMedGoogle Scholar
  116. 116.
    Meltzer HY, Hippius H. The assessment and the management of treatment resistant schizophrenia in perspective. Eur Psychiatry 1995; 1 Suppl. 10: 3s–5sCrossRefGoogle Scholar
  117. 117.
    Gillin JC, Byerey WF. The diagnosis and management of insomnia. N Engl J Med 1990; 322: 239–48CrossRefPubMedGoogle Scholar
  118. 118.
    Gillin JC. The long and the short of sleeping pills. N Engl J Med 1991; 324: 1735–6CrossRefPubMedGoogle Scholar
  119. 119.
    Reynolds CF, Boysse DJ, Kupfer DJ. Developmental and biopsychosocial perspectives on the diagnosis and treatment of persistent insomnia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1617–29Google Scholar
  120. 120.
    Morselli PL, Guillet P. Drug development in the elderly: problems and constraints. In: Burley D, Haward CH, Mullinger B, editors. The focus for pharmaceutical knowledge. London: Macmillan, 1988: 204–21Google Scholar
  121. 121.
    Lauka PV, Hoffman NB. Decreasing medication use in a nursing-home patient care unit. Am J Hosp Pharm 1992; 49: 96–9Google Scholar
  122. 122.
    Koecheler-Schneider J, Mion LC, Frengley JD. Adverse drug reactions in an elderly out-patient population. Am J Hosp Pharm 1992; 49: 90–6Google Scholar
  123. 123.
    Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinical visits. Arch Intern Med 1990; 150: 1509–10CrossRefPubMedGoogle Scholar
  124. 124.
    Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sakett DL, editors. Compliance in health care. Baltimore, London: John Hopkins University Press, 1979: 1–7Google Scholar
  125. 125.
    Darnell JC, Murray MD, Marz BL, et al. Medication use by ambulatory elderly: an in home survey. J Am Geriatr Soc 1986; 49: 1–4Google Scholar
  126. 126.
    Spagnoli A, Ostino G, Borga AD, et al. Drug-compliance and unreported drugs in the elderly. J Am Geriatr Soc 1989; 37: 619–24PubMedGoogle Scholar
  127. 127.
    American Association for the Retired Person. A survey on the need for a prescription drug benefit under the Medicare Program. Washington (DC): AARP, 1992 JunGoogle Scholar
  128. 128.
    Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990; 38: 1290–5PubMedGoogle Scholar
  129. 129.
    Leppick IE. How to get patients with epilepsy to take their medication: the problem of noncompliance. Postgrad Med 1990; 88: 253–6Google Scholar
  130. 130.
    Bloom BS. The medical, social and economic implications of disease. In: Van Eimeren W, Horisberg B, editors. Socio-economic evaluation of drug therapy. Berlin, New York: Springer Verlag 1988: 3–11Google Scholar
  131. 131.
    Clark LT. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 1991; 121: 664–9CrossRefPubMedGoogle Scholar
  132. 132.
    Kruse WH. Compliance with treatment of hyperlipoproteinemia in medical practice and clinical trials. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 175–86Google Scholar
  133. 133.
    Squire A, Goldman ME, Kupersmith J, et al. Long-term antiarrhythmic therapy: problem of low drug levels and patient noncompliance. Am J Med 1984; 77: 1038CrossRefGoogle Scholar
  134. 134.
    Vandel B, Vandel S. Facteurs pharmacocinétiques et résistance aux traitements antidepresseurs. Encephale 1986; 12: 217–22PubMedGoogle Scholar
  135. 135.
    Dinan TG. A rational approach to the non-responding depressed patient. Int Clin Psychopharmacol 1993; 8: 221–3CrossRefPubMedGoogle Scholar
  136. 136.
    Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21: 833–4PubMedGoogle Scholar
  137. 137.
    Nagasawa M, Smith MC, Barnes JH. Meta-analysis of correlates of diabetes patient’s compliance with prescribed medications. Diabetes Educ 1990; 16: 192–200CrossRefPubMedGoogle Scholar
  138. 138.
    Joglekar M, Mohanaruban K, Bayer AJ, et al. Can old people on anticoagulant be safely managed as out-patients? Postgrad Med J 1988; 14: 775–7CrossRefGoogle Scholar
  139. 139.
    Bauman AE, Craig AR, Dunsmore J, et al. Removing barriers to effective self-management of Asthma. Patient Educ Couns 1989; 14: 217–26CrossRefGoogle Scholar
  140. 140.
    Hemminki E, Brambilla DJ, McKinlay SM, et al. Use of estrogens among middle-aged Massachussetts women. DICP 1991; 25: 418–23PubMedGoogle Scholar
  141. 141.
    Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed?. A novel assessment technique. JAMA 1989; 261: 3273–7CrossRefPubMedGoogle Scholar
  142. 142.
    Kruse W, Weber E. Dynamics of drug regimen compliance — its assessment by microprocessor based monitoring. Eur J Clin Pharmacol 1990; 38: 561–5CrossRefPubMedGoogle Scholar
  143. 143.
    Rudd P, Ahmed S, Zachary V, et al. Improved compliance measures: application in an ambulatory antihypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676–85CrossRefPubMedGoogle Scholar
  144. 144.
    Krall R. Effect of patient compliance on safety. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 19–25Google Scholar
  145. 145.
    Beardon PHG. Primary non compliance with prescribed medications in primary care. BMJ 1993; 307: 846–8CrossRefPubMedGoogle Scholar
  146. 146.
    Kruse W, Schlierf G, Weber E. Monitoring compliance in clinical trials. Lancet 1990; 335: 803–4CrossRefPubMedGoogle Scholar
  147. 147.
    Editorial. Patient compliance in clinical trials. Lancet 1993; 337: 823–4Google Scholar
  148. 148.
    Nies A. Sources of drug information. In: Goodman Gilman A, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. New York: McGraw-Hill Inc., 1989: 80–1Google Scholar
  149. 149.
    Mushlin AJ, Appel FA. Diagnosing potential noncompliance: physician’s ability in a behavioral dimension of medical care. Arch Intern Med 1977; 150: 318–31CrossRefGoogle Scholar
  150. 150.
    Norrell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med 1981; 15: 57–61CrossRefGoogle Scholar
  151. 151.
    Kruse W, Schlierf G, Weber E. Continuous compliance monitoring: its utility for the interpretation of drug trials. Eur J Clin Pharmacol 1989; 36 Suppl. A: 289Google Scholar
  152. 152.
    Spilker B. Methods of assessing and improving patient compliance in clinical trials. In: Cramer JA, Spilker B. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 37–56Google Scholar
  153. 153.
    Cramer JA. Identifying and improving compliance patterns: a composite plan for health care providers. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991: 387–92Google Scholar
  154. 154.
    Efron B, Feldman D. Compliance as explanatory variable in clinical trials. J Am Stat Assoc 1991; 86: 9–26CrossRefGoogle Scholar
  155. 155.
    Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press 1991; 265–81Google Scholar
  156. 156.
    Morselli PL, Cazor JL. The benefit/risk ratio during the development of a new drug. In: Boissel JP, Caulin, Teule M, editors. Recent trends in clinical pharmacology. Colloque INSERM 205. London, Paris: John Libbey 1991: 175–86Google Scholar
  157. 157.
    Morselli PL, Baruzzi A, Bossi L, et al. Intensive long-term monitoring in resistant epileptic patients: results of a two-year study. In: Wada A, Penry JK, editors. Advances in epileptology. Xth Epilepsy International Symposium. New York: Raven Press 1980; 99–107Google Scholar
  158. 158.
    Sjöqvist F. Polymorphic drug oxidation: implication for therapeutic drug monitoring. In: Alvan G, Balant LP, Bechtel PR, et al., editors. European Consensus Conference on Pharmacogenetics. EUR 12379-EN. Bruxelles, Luxembourg: European Commission, 1990; 97–106Google Scholar
  159. 159.
    Monaco F, Riccio A, Benna, et al. Further observations on carbamazepine plasma levels in epileptic patients. Neurology 1976; 26: 936–43CrossRefPubMedGoogle Scholar
  160. 160.
    Milano Collaborative Group for Studies on Epilepsy. Longterm intensive monitoring in the difficult patient: preliminary results of 16 months’ observations. Usefulness and limitations. In: Gardner-Thorpe C, Janz D, Meinardi H, et al, editors. Antiepileptic drug monitoring. Kent: Pitman Medical, 1977: 197–212Google Scholar
  161. 161.
    Loiseau P, Battellocchi S, Brachet-Liermain AB, et al. Evaluation of the role of plasma level monitoring and its consequences in the therapeutic management of epileptics: a longitudinal study with phenobarbitone and phenytoin in 242 patients. In: Johannessen S, Morselli PL, Pippenger CE, et al., editors. Antiepileptic therapy: advances in drug monitoring. New York: Raven Press, 1980: 271–6Google Scholar
  162. 162.
    Loo H, Benyacoub AK, Rovei V, et al. Long-term monitoring of tricyclic antidepressant plasma concentrations. Br J Psychiatry 1980; 137: 444–51CrossRefPubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Pau Salvà Lacombe
    • 1
    • 2
  • Juan Antonio García Vicente
    • 1
    • 2
  • Joan Costa Pagès
    • 1
    • 2
  • Paolo Lucio Morselli
    • 1
    • 2
  1. 1.Clinical Pharmacology DepartmentUniversity Hospital ‘Germans Trias i Pujol’, Universitat Autònoma de BarcelonaBarcelonaSpain
  2. 2.Clinical Pharmacology DepartmentUniversity Hospital ‘Germans Trias i Pujol’BadalonaSpain

Personalised recommendations